[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647262":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":10,"responsibleParty":34,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":60,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":10},{"fullName":5,"class":6},"University Hospital, Montpellier","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients Suspected of ALS",null,"This group of patients includes those with a suspected diagnosis of ALS and referred to the CHU Montpellier reference center. The study focuses on measuring serum levels of neurofilament light (NfL), a biomarker of neuronal damage, to assess its ability to diagnose ALS and predict disease progression, survival and timing of initiation of non-invasive ventilation (NIV).",[13],"Diagnostic Test: Serum Neurofilament Serum NfL Measurement",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Serum Neurofilament Serum NfL Measurement","The procedure involves taking an additional 6 ml blood sample (dry tube) during the first visit, in addition to the routine sample taken for diagnostic investigations. Serum levels of neurofilament light chain (NfL), a biomarker of neuronal damage, will be measured using ultrasensitive techniques (SIMOA, Lumipulse, Cobas). The aim is to assess the diagnostic performance of NfL levels in differentiating ALS from other neurodegenerative diseases, as well as their prognostic value in terms of survival and disease progression.",[9],[21],{"name":22,"affiliation":5,"role":23},"Elisa DE LA CRUZ, MD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":22,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","04 67 33 02 81","+33","e-delacruz@chu-montpellier.fr",{"name":31,"role":26,"phone":32,"phoneExt":28,"email":33},"Florence ESSELIN, MD","04 67 33 75 05","f-esselin@chu-montpellier.fr",{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100647262","serum-neurofilaments-in-the-diagnosis-of-amyotrophic-lateral-sclerosis-100647262",false,"NCT07706270","Serum Neurofilaments in the Diagnosis of Amyotrophic Lateral Sclerosis","Diagnostic Performance of Serum Neurofilaments in the Differential Diagnosis of Amyotrophic Lateral Sclerosis","DIAGONALS","Inclusion Criteria:\n\n* Be at least 18 years of age\n* Be able to undergo blood sampling (however, blood sampling is part of the standard examination and will not be performed exclusively for this study).\n* Patients with suspected ALS\n\nExclusion Criteria:\n\n-• Patients with recent stroke\n\n* Pregnant or breast-feeding women\n* Patient deprived of liberty by judicial or administrative decision, or hospitalization under duress\n* Adult protected by law (guardianship, curatorship)\n* Patient unable to understand and read information and consent forms in French\n* Person participating in another research study with an exclusion period still in progress.\n* Failure to obtain written informed consent after a period of reflection\n* Not affiliated to a social security scheme or beneficiary of such a scheme\n* Person unable to give consent","ALL","18 Years",{"count":47,"type":48},138,"ESTIMATED","OBSERVATIONAL","Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease, often difficult to diagnose due to symptoms similar to other neurological pathologies. Diagnosis can take up to 14 months, although the rapid progression of the disease requires early detection. At present, there is no validated biomarker to aid diagnosis. Serum neurofilaments light chain (NfL), markers of neuronal degeneration, show great potential to help diagnose ALS early and assess disease severity. Recent research has shown that measurement of NfL in the blood can differentiate ALS from other neurological disorders, and new technologies are increasingly making it possible to perform these tests clinically.\n\nThe study hypothesis is that NfL blood levels, measured using clinical analyzers, could improve early ALS diagnosis, optimize patient recruitment for therapeutic trials and accelerate the assessment of treatment efficacy.\n\nThe primary objective is to evaluate the sensitivity and specificity of serum NfL for the diagnosis and differential diagnosis of amyotrophic lateral sclerosis (ALS) in newly recruited patients referred to the ALS Reference Center at Montpellier University Hospital. The diagnosis is established according to the revised El Escorial diagnostic criteria (see Appendix). This diagnosis is determined independently of the serum NfL concentration.",[52,53,54],"Amyotrophic Lateral Sclerosis (ALS)","Neurodegenerative Disorders","Motor Neuron Diseases",[56,57,58,59],"amyotrophic lateral sclerosis","neurofilament proteins","glial fibrillary acid protein","early diagnosis","NOT_YET_RECRUITING","2026-07-16",{"date":63,"type":64},"2026-07-20","ACTUAL",{"date":66,"type":48},"2026-08-01",{"date":68,"type":48},"2028-08-01",{"name":5,"class":6}]